Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States14 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating Novel Therapies in ctDNA Positive GI Cancers | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gallbladder adenocarcinoma, gastric adenocarcinoma, hepatocellular carcinoma, intestinal disorder, liver disorder, neoplasm, pancreatic adenocarcinoma, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-06 | NCT05482516 | |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT06472245 | |
| BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT05558982 | |
| Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-06-30 | NCT06015724 | |
| Male Breast Cancer: Understanding the Biology for Improved Patient Care | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-05-12 | NCT01101425 | |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-27 | NCT05440708 | |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myeloid leukemia, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-03-24 | NCT04988555 | |
| Phase IB/II of CPX-351 for Relapse Prevention in AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-03-23 | NCT04990102 | |
| Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-03-16 | NCT04499053 | |
| NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | KRAS Mutation-Related Tumors; Solid Tumor | Recruiting | Phase 1 | 2026-03-06 | NCT05661201 | |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | Cancer Related Cognitive Decline; Non-metastatic Breast Cancer | Recruiting | Phase 1 / Phase 2 | 2025-12-24 | NCT05256745 | |
| Addressing Genomic Disparities in Cancer Survivors | Genetic Testing; Hereditary Cancer | Recruiting | Not applicable | 2025-10-28 | NCT06073626 | |
| CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing | Adnexal Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hereditary breast ovarian cancer syndrome, hereditary disease, hereditary neoplastic syndrome, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, skin disorder | Recruiting | Not applicable | 2025-08-28 | NCT05130606 | |
| FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-07-02 | NCT06669117 |